Late Breaking Abstract - Efficacy and safety of benralizumab in patients with severe uncontrolled asthma despite ICS-LABA: a randomised, double-blind, placebo-controlled phase 3 trial in Asia (MIRACLE)

被引：0

作者：

Lai, Kefang ^{[1
]}

Sun, Dejun ^{[2
]}

Dai, Ranran ^{[3
]}

Samoro, Ronnie ^{[4
]}

Park, Hae-Sim ^{[5
]}

Astrand, Annika ^{[6
]}

Cohen, David ^{[7
]}

Jison, Maria ^{[7
]}

Shih, Vivian ^{[8
]}

Werkstrom, Viktoria ^{[6
]}

Yao, Yuhui ^{[9
]}

Zhang, Yajuan ^{[9
]}

Zheng, Wenying ^{[10
]}

Zhong, Nanshan ^{[1
]}

机构：

[1] Guangzhou Med Univ, State Key Lab Resp Dis, Natl Clin Res Ctr Resp Dis, Guangzhou Inst Resp Hlth,Affiliated Hosp 1, Guangzhou, Peoples R China

[2] Inner Mongolia Peoples Hosp, Hohhot, Peoples R China

[3] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Shanghai, Peoples R China

[4] Healthlink Med Surg Dent Clin & Diagnost Ctr, Iloilo, Philippines

[5] Ajou Univ Hosp, Suwon, South Korea

[6] AstraZeneca, Late Stage Resp & Immunol, Gothenburg, Sweden

[7] AstraZeneca, Late Stage Resp & Immunol, Gaithersburg, MD USA

[8] AstraZeneca, BioPharmaceut Med, Gaithersburg, MD USA

[9] AstraZeneca, Resp & Immunol, R&D China, Shanghai, Peoples R China

[10] AstraZeneca, R&D China, Biometr, Shanghai, Peoples R China

来源：

EUROPEAN RESPIRATORY JOURNAL | 2023年 / 62卷

关键词：

D O I：

10.1183/13993003.congress-2023.PA4130

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

引用

页数：3

共 50 条

[21] NAVIGATOR: a phase 3 multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma
Andrew Menzies-Gow
Gene Colice
Janet M. Griffiths
Gun Almqvist
Sandhia Ponnarambil
Primal Kaur
Gennaro Ruberto
Karin Bowen
Åsa Hellqvist
May Mo
Esther Garcia Gil
Respiratory Research, 21
[22] Efficacy and safety of linaclotide in treating functional constipation in paediatric patients: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
Di Lorenzo, Carlo
Khlevner, Julie
Rodriguez-Araujo, Gerardo
Xie, Wangang
Huh, Susanna Y.
Ando, Masakazu
Hyams, Jeffrey S.
Nurko, Samuel
Benninga, Marc A.
Simon, Michael
Hewson, Marcella E.
Saps, Miguel
LANCET GASTROENTEROLOGY & HEPATOLOGY, 2024, 9 (03): : 238 - 250
[23] Safety and efficacy of satralizumab in patients with generalised myasthenia gravis (LUMINESCE): a randomised double-blind, multicentre, placebo-controlled phase 3 trial
Habib, Ali A.
Zhao, Chongbo
Aban, Inmaculada
Franca Jr, Marcondes Cavalcante
Jose, Jorge Gustavo
Hoerste, Gerd Meyer zu
Klimiec-Moskal, Elzbieta
Pulley, Michael T.
Tavolini, Dario
Krumova, Petranka
Lennon-Chrimes, Sian
Smith, Jillian
Thanei, Gian-Andrea
Blondeau, Kathleen
Vodopivec, Ivana
Wolfe, Gil, I
Murai, Hiroyuki
LANCET NEUROLOGY, 2025, 24 (02): : 117 - 127
[24] NAVIGATOR: a phase 3 multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma
Menzies-Gow, Andrew
Colice, Gene
Griffiths, Janet M.
Almqvist, Gun
Ponnarambil, Sandhia
Kaur, Primal
Ruberto, Gennaro
Bowen, Karin
Hellqvist, Asa
Mo, May
Garcia Gil, Esther
RESPIRATORY RESEARCH, 2020, 21 (01)
[25] Efficacy and Safety of Lebrikizumab in Severe Uncontrolled Asthma: Results from the Lute and Verse Phase II Randomized, Double-Blind, Placebo-Controlled Trials
Hanania, Nicola A.
Noonan, Michael J.
Corren, Jonathan
Korenblat, Phillip
Zheng, Yanan
Putnam, Wendy
Murray, Elaine
Abelardo, Connie
Scheerens, Heleen
Maciuca, Romeo
Gray, Sarah
Doyle, Ramona
McClintock, Dana
Matthews, John G.
Yen, Karl
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2014, 133 (02) : AB402 - AB402
[26] Efficacy and safety of fevipiprant in patients with uncontrolled asthma: Two replicate, phase 3, randomised, double-blind, placebo-controlled trials (ZEAL-1 and ZEAL-2)
Castro, Mario
Kerwin, Edward
Miller, David
Pedinoff, Andrew
Sher, Lawrence
Cardenas, Pamela
Knorr, Barbara
Lawrence, David
Ossa, Diego
Wang, Wei
Maspero, Jorge F.
ECLINICALMEDICINE, 2021, 35
[27] Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials
Panettieri, Reynold A., Jr.
Sjobring, Ulf
Peterffy, AnnaMaria
Wessman, Peter
Bowen, Karin
Piper, Edward
Colice, Gene
Brightling, Christopher E.
LANCET RESPIRATORY MEDICINE, 2018, 6 (07): : 511 - 525
[28] Benralizumab for eosinophilic gastritis: a single-site, randomised, double-blind, placebo-controlled, phase 2 trial
Kliewer, Kara L.
Murray-Petzold, Cristin
Collins, Margaret H.
Abonia, Juan P.
Bolton, Scott M.
Ditommaso, Lauren A.
Martin, Lisa J.
Zhang, Xue
Mukkada, Vincent A.
Putnam, Philip E.
Kellner, Erinn S.
Devonshire, Ashley L.
Schwartz, Justin
Kunnathur, Vidhya A.
Rosenberg, Chen E.
Lyles, John L.
Shoda, Tetsuo
Klion, Amy
Rothenberg, Marc E.
LANCET GASTROENTEROLOGY & HEPATOLOGY, 2023, 8 (09): : 803 - 815
[29] Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial
Cid, Maria C.
Unizony, Sebastian H.
Blockmans, Daniel
Brouwer, Elisabeth
Dagna, Lorenzo
Dasgupta, Bhaskar
Hellmich, Bernhard
Molloy, Eamonn
Salvarani, Carlo
Trapnell, Bruce C.
Warrington, Kenneth J.
Wicks, Ian
Samant, Manoj
Zhou, Teresa
Pupim, Lara
Paolini, John F.
ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 (05) : 653 - 661
[30] Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
Cheng, Ann-Lii
Kang, Yoon-Koo
Chen, Zhendong
Tsao, Chao-Jung
Qin, Shukui
Kim, Jun Suk
Luo, Rongcheng
Feng, Jifeng
Ye, Shenglong
Yang, Tsai-Sheng
Xu, Jianming
Sun, Yan
Liang, Houjie
Liu, Jiwei
Wang, Jiejun
Tak, Won Young
Pan, Hongming
Burock, Karin
Zou, Jessie
Voliotis, Dimitris
Guan, Zhongzhen
LANCET ONCOLOGY, 2009, 10 (01): : 25 - 34

← 1 2 3 4 5 →